Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of BMS-986012 With Carboplatin, Etoposide and Nivolumab in First-line Extensive-stage Small Cell Lung Cancer
2024-510700-36-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of Atigotatug in small cell lung cancer (SCLC), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events (AEs), Incidence of serious adverse events (SAEs) and 3 more. Started Jun 2024; status: completed.
02
Drugs
Atigotatug
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-510700-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510700-36-00.